| __timestamp | Celldex Therapeutics, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 3788000000 |
| Thursday, January 1, 2015 | 4011000 | 4006000000 |
| Friday, January 1, 2016 | 102026000 | 4261000000 |
| Sunday, January 1, 2017 | 96171000 | 4371000000 |
| Monday, January 1, 2018 | 66449000 | 4853000000 |
| Tuesday, January 1, 2019 | 42672000 | 4675000000 |
| Wednesday, January 1, 2020 | 42534000 | 4572000000 |
| Friday, January 1, 2021 | 3068000 | 6601000000 |
| Saturday, January 1, 2022 | 1400000 | 5657000000 |
| Sunday, January 1, 2023 | 3008000 | 6498000000 |
| Monday, January 1, 2024 | 28675800000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. Gilead Sciences, Inc. and Celldex Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Gilead's cost of revenue consistently dwarfed that of Celldex, peaking at approximately $6.6 billion in 2021. This represents a staggering 74% increase from its 2014 figures. Meanwhile, Celldex's costs remained relatively modest, with a high of around $102 million in 2016, a mere fraction of Gilead's expenditures.
These trends highlight the diverse strategies and market positions of these biotech leaders.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Johnson & Johnson vs Gilead Sciences, Inc.
Cost of Revenue Trends: AstraZeneca PLC vs Gilead Sciences, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Zoetis Inc.
Cost Insights: Breaking Down Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited's Expenses
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.